Baseline characterisics for all patients and divided according to eGFR with the CKD-EPI equation
| All | Subgroup with atrial fibrillation | |
| N=40 736 | N=20 976 | |
| Age (years), median (IQR) | 77 (67–84) | 79 (71–85) |
| Female | 38.2% | 38.9% |
| Diabetes | 25.2 % | 23.4% |
| Hypertension | 49.1% | 50.0% |
| Ischaemic heart disease | 48.7% | 42.4% |
| Married/cohabitant | 55.4% | 54.4% |
| Duration of heart failure <6 months | 51.4% | 46.4% |
| Inpatient registration | 66.6% | 71.1% |
| Atrial fibrillation (history of and/or on ECG) | 51.5% | 100% |
| ECG with atrial fibrillation at visit/hospitalisation | 39.1% | 75.8% |
| Device therapy | ||
| Pacemaker | 9.2% | 11.3% |
| ICD/CRT/CRT-D | 4.0% | 3.8% |
| NYHA | ||
| 1 | 11.2% | 9.5% |
| 2 | 45.3% | 44.4% |
| 3 | 38.6% | 41.4% |
| 4 | 4.8% | 5.2% |
| Echocardiography findings | ||
| LVEF ≥50% | 21.80% | 25.6% |
| LVEF 40%–49% | 20.50% | 21.9% |
| LVEF 30%–39% | 27.60% | 26.3% |
| LVEF <30% | 30.10% | 26.3% |
| Treatment year | ||
| 2000–2006 | 22.50% | 21.7% |
| 2007–2012 | 77.50% | 78.3% |
| Renal function | ||
| Creatinine (mmol/L), median (IQR) | 97 (79–125) | 100 (81–128) |
| CKD-EPI eGFR (mL/min/1.73 m2), median (IQR) | 59 (42–77) | 56 (41–73) |
| MDRD eGFR (mL/min/1.73 m2), median (IQR) | 59 (43–75) | 57 (42–72) |
| Cockcoft-Gault eGFR (mL/min), median (IQR) | 57 (39–82) | 53 (37–75) |
| BSA* | ||
| BSA, median (IQR) (missing) | 1.90 (1.75–2.06) (21 141) | 1.91 (1.75–2.06) (11 036) |
| Current medication | ||
| ACE inhibitor/angiotensin receptor blocker | 80.9% | 79.3% |
| Beta-blockers | 85.1% | 86.6% |
| Loop-diuretic | 24.7% | 27.8% |
| Digoxin | 17.9% | 30.2% |
| Statins | 43.2% | 36.2% |
| Antiplatelets | 52.0% | 38.5% |
| Anticoagulants | 36.9% | 58.2% |
*BSA estimated with the DuBois and DuBois formula,17 which is based on weight (kg) and height (cm) (BSA = (weight0.425 x height0.725) x 0.007184).
BSA, body surface area; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; ICD, International Classification of Diseases; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease Study; NYHA, New York Heart Association.